Ingenuity is at the center of pharmacy care

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications. We continue to closely monitor the FDA landscape to help provide our audiences with an understanding of the current drug and biologic market.

How did we keep trend and spend down despite the effects of utilization, inflation, and new drugs introduced to the market? By implementing multiple mitigation strategies — and using our integrated approach to whole-person health.

Read our 2021 Drug Trend Report to learn more.  

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest. Open the attachment to learn about:

1. Insights on a gene therapy in development for cerebral adrenoleukodystrophy (CALD).
2. Potential new treatments for amyotrophic lateral sclerosis (ALS) and psoriasis.
3. Other select significant product approvals expected in 2022 and 2023.
4. The latest on Humira® biosimilars and a gene therapy for hemophilia A previously delayed by the FDA.
5. An update on beta amyloid products for Alzheimer’s disease and a focus on agents for dry age-related macular degeneration (AMD).